CBLL
CBLLHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeHeadquartered within the healthcare sector, CBLL focuses on Medical Devices services and products. CBLL operates as a medical technology company in the United States. Valued at $710.3M, CBLL is a small-cap name in its sector. It develops the Ceribell System, a novel and point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting.
Market Cap
$710.3M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-17.04
EPS (TTM)
$-1.58
EPS (Fwd)
$-1.10
ROE
-37.5%
ROA
-20.7%
Cash
$141.2M
Total Debt
$22.1M
Free CF
-$29.3M
52W Change
20.2%
Annual Financials
Cash vs Debt
With $141.2M in cash and $22.1M in debt, CBLL maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$29.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -37.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $25.9M (2022) to $89.1M (2025), reflecting a 244% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CBLL.